Why Reforming the U.S. Pharma Industry May Prove Difficult for Trump

 Former President Donald Trump has revived his pledge to lower prescription drug prices if re-elected. However, systemic barriers—including entrenched pharmaceutical lobbying, complex regulatory pathways, and economic reliance on pharma innovation—make substantial reform challenging. Even previously proposed measures faced legal pushback and political gridlock. While populist rhetoric on drug pricing appeals to voters, actual structural reform is likely to be slow and contentious.





If you can provide the article text, I can rewrite the entire piece for you.

Comments

Popular posts from this blog

“It’s breathtaking”: “Shot on iPhone” videos win award at Cannes

Harnessing Innovation with Rajesh Joshi Chariot Media for Market Leadership

Baroness bruck twitter